MedTrace Logo

Combined Approach to Resection of Glioblastoma (GBM) by 5-Aminolevulinic Acid (5-ALA) and Intraoperative Magnetic Resonance Imaging (MRI)

NCT01208909 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2010-10-22

No results posted yet for this study

Summary

In the treatment of glioblastoma (GBM) neurosurgical resection of the tumor is usually considered a a first step of effective therapy. Radical resection of the tumor is highly beneficial to the patient as measured in progression-free survival and overall survival. At the same time eloquent areas of the brain have to remain intact to preserve quality of life.

Both 5-ALA fluorescence and intraoperative MRI are used for intraoperative marking of tumor tissue and thereby to improve precision of GBM-Resection.

We now study whether the combination of 5-ALA fluorescence and intraoperative MRI increases the number of sites where tumor tissue can be detected.

\- Trial with surgical intervention

Conditions

Interventions

PROCEDURE

diagnostic 5-ALA and MRI for tumor resection

diagnostic 5-ALA and MRI for tumor resection

Sponsors & Collaborators

  • University of Zurich

    lead OTHER

Principal Investigators

  • René L Bernays, MD · UniversitaetsSpital Zuerich

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2011-12-31
Completion
2011-12-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01208909 on ClinicalTrials.gov